Odyssey Therapeutics, Inc. (NasdaqCM: ODTX)
Health Care · Biotechnology · US
$19.00
-8.32% today · +15.7% 1Y
Odyssey Therapeutics, Inc. (NasdaqCM: ODTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $910.45M and employs 100 people.
Over the last twelve months the share price has gained 15.7%, trading between 15.10 and 29.05.
Tweenvest scores Odyssey Therapeutics, Inc. across four factors: quality 44/100, value 61/100. Its strongest factor is value.
ODTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $910.45M
- Revenue (TTM)
- $99.00K
- P/E
- —
- EPS
- -14.05
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $29.05
- 52-week low
- $15.10
- Avg volume (3M)
- —
- Shares outstanding
- 47.92M
- Employees
- 100
- Next earnings
- —
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
- ISIN
- US67613T1043
- Founded
- 2021
- Listed since
- May 8, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| LongBio Pharma (Suzhou) Co., Ltd.SEHK: 1779 | $926.52M | HK$98.00 | -3.64% |
| MoonLake ImmunotherapeuticsNasdaqCM: MLTX | $920.85M | $10.82 | +2.27% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $916.81M | $49.08 | +0.74% |
| Jade Biosciences, Inc.NasdaqCM: JBIO | $915.17M | $14.34 | -0.35% |
| Alphamab OncologySEHK: 9966 | $907.71M | HK$7.36 | -11.44% |
| Frontier Biotechnologies Inc.SHSE: 688221 | $886.38M | CN¥15.85 | -6.05% |
| Corvus Pharmaceuticals, Inc.NasdaqGM: CRVS | $884.95M | $10.45 | -0.67% |
| Beijing SL Pharmaceutical Co., Ltd.SZSE: 002038 | $883.46M | CN¥5.76 | +0.17% |
Figures last refreshed Oct 11, 2026.